NCT06095596View on ClinicalTrials.gov

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

NARecruitingINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Ulcerative Colitis (UC)
Interventions
DRUG

Upadacitinib

Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.

DRUG

Vedolizumab

Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.

Trial Locations (1)

501655

RECRUITING

the Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sixth Affiliated Hospital, Sun Yat-sen University

OTHER